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Abstract
Background: Optimal type 1 diabetes mellitus (T1D) care requires lifelong appropriate insulin treatment, which can
be provided either by multiple daily injections (MDI) of insulin or by continuous subcutaneous insulin infusion (CSII).
An increasing number of trials and previous systematic reviews and meta-analyses (SRMA) have compared both CSII
and MDI but have provided limited information on equity and fairness regarding access to, and the effect of, those
insulin devices. This study protocol proposes a clear and transparent methodology for conducting a SRMA of the
literature (1) to assess the effect of CSII versus MDI on glycemic and patient-reported outcomes (PROs) among
young patients with T1D and (2) to identify health inequalities in the use of CSII.
Methods: This protocol was developed based on the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis Protocols (PRISMA-P), the PRISMA-E (PRISMA-Equity 2012 Guidelines), and the Cochrane Collaboration
Handbook. We will include randomized clinical trials and non-randomized studies published between January 2000
and June 2019 to assess the effectiveness of CSII versus MDI on glycemic and PROs in young patients with T1D. To
assess health inequality among those who received CSII, we will use the PROGRESS framework. To gather relevant
studies, a search will be conducted in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL),
the Cochrane Database of Systematic Reviews, and the Health Technology Assessment (HTA) database. We will
select studies that compared glycemic outcomes (the glycosylated hemoglobin values, severe hypoglycemia
episodes, diabetic ketoacidosis events, and/or time spent in range or in hyper-hypoglycemia), and health-related
quality of life, as a PRO, between therapies. Screening and selection of studies will be conducted independently by
two researchers. Subgroup analyses will be performed according to age group, length of follow-up, and the use of
adjunctive technological therapies that might influence glycemic outcomes.
Discussion: Studies of the average effects of CSII versus MDI may have not assessed their impact on health equity,
as some intended populations have been excluded. Therefore, this study will address health equity issues when
assessing effects of CSII. The results will be published in a peer-review journal. Ethics approval will not be needed.
Systematic review registration: PROSPERO CRD42018116474
Keywords: Insulin pump, Continuous subcutaneous insulin infusion, Multiple daily injections, Health inequity, Type
1 diabetes
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Background
Optimal type 1 diabetes mellitus (T1D) care requires
lifelong appropriate insulin treatment that can be pro-
vided by either multiple daily injections (MDI) of insulin
or by a continuous subcutaneous insulin infusion (CSII)
pump [1]. Over the last years, the use of CSII has in-
creased substantially among pediatric patients [1]. How-
ever, the selection of CSII versus MDI might have not
been based only on clinical indications (e.g., elevated gly-
cosylated hemoglobin and higher hypoglycemia rate),
but also could have been influenced by social factors,
such as the place of residence and socioeconomic status,
which may have led to health inequalities [1–3].
Meeting glycemic targets is a challenging task in young
patients with T1D; thus, new insulin delivery systems
represent an opportunity to improve glycemic control,
to promote patient-centered decisions, and to reduce the
burden of diabetes care [4, 5]. Although an increasing
number of trials has assessed whether the CSII is more
effective than the intensive insulin therapy with syringe
and/or pen [6–13], previous systematic reviews and
meta-analyses (SRMA) of trials have not reported ad-
equate information concerning equity and fairness in
treatment selection [14–17].
Given the greater difficulty for good glycemic control
in patients/families with lower health literacy and poor
access to some healthcare resources, it is possible that
the absolute benefit of CSII would be greater in those
with lower socioeconomic status [18]. However, we do
not know if they have the chance to participate and
benefit from this intervention. In addition, there might
exist several barriers for patient access and/or mainten-
ance using CSII, and only a few studies (e.g., diabetes
registries) have investigated the role of unequal health
care access and social disparities on glycemic outcomes
[2, 19, 20]. In consequence, SRMAs with an equity lens
could assess whether unequal benefits across sociodemo-
graphic population groups could contribute to worsen-
ing health inequalities in T1D management [21–23].
Therefore, this paper aims to report a standardized
and transparent methodology for conducting a SRMA of
the literature (1) to assess the effectiveness of using CSII
versus MDI on glycemic (glycosylated hemoglobin, se-
vere hypoglycemia, diabetes ketoacidosis and glycemic
variability) and patient-related outcomes among young
patients with T1D and (2) to identify health inequalities
for those who use CSII.
Methods
Review design
This protocol was developed based on the Preferred
Reporting Items for Systematic Reviews and Meta-
Analysis Protocols (PRISMA-P) [24] and was registered
and published on PROSPERO international prospective
register of systematic reviews (registration number
CRD42018116474). The Cochrane Collaboration Hand-
book [25] will also be used to guide the review methods,
and PRISMA-E (PRISMA-Equity 2012) Guidelines [26] to
elaborate the final report. To perform the SRMA, we will
include randomized clinical trials (RCT) and non-
randomized studies (NRS)—which cover diabetes regis-
tries and longitudinal studies—that compared the clinical
effectiveness of CSII versus MDI in youths with T1D.
Data sources and search strategy
The bibliographic search will be conducted from January
2000 to June 2019 in MEDLINE (via PubMed), EMBASE,
Cochrane Central Register of Controlled Trials (CEN-
TRAL), the Cochrane Database of Systematic Reviews,
and the Health Technology Assessment (HTA) Database.
We will also carry out a handsearch of the previous re-
views and the bibliography from the original articles for
additional references, as well as of the gray literature
focusing on abstracts from diabetes associations and
conference proceedings, and from technical reports (re-
search and governmental agencies). Search will use stan-
dardized subject terms and will be conducted by a
librarian with the input from the principal investigator,
using Boolean operators for MEDLINE, EMBASE, CEN-
TRAL, and HTA database. The final search strategy will
have no restrictions based on language or publication sta-
tus (see Additional file 1).
Eligibility criteria
We will select studies that compared the use of CSII with
MDI and evaluated any of the following glycemic out-
comes: glycosylated hemoglobin (HbA1c, percentage), the
incidence of hypoglycemia episodes [e.g., severe, serious
and/or nocturnal], diabetic ketoacidosis (DKA) events,
and/or time spent in range or in hyper-hypoglycemia.
Studies that mentioned health-related quality of life
(HRQoL) as a PRO will also be selected. Specifically, the
studies must meet the following selection criteria: (1) to
be conducted with children and adolescents (under 20
years of age), (2) exclusively on patients with T1D, (3)
designed as RCT or NRS, and (4) to have reported any of
the outcomes of interest: HbA1c, hypoglycemia, DKA,
time in range or in hyper-hypoglycemia, and HRQoL. Bi-
hormonal or dual-hormone closed-loop systems that de-
liver glucagon in addition to insulin will not be included.
Equity analysis
To explore equity in CSII, we will use indicators of so-
cial disadvantages defined by PROGRESS [27]. The acro-
nym PROGRESS is a framework to guide data extraction
to relate the outcomes with equity of access to an inter-
vention, according to “place of residence” (residing in a
high- or low-to-middle-income country, as per the
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World Bank database), “race, ethnicity, culture and lan-
guage” (racial, ethnical, and cultural background, when
the majority of the groups include belonging to a
distinctive group who shares origin, culture, traditions,
and language through generations), “occupation” (paren-
tal patterns of work that favor proper maintenance of a
therapy or not), “gender/sex” (sex refers to identify sex
distribution when recommended each therapy), “reli-
gion” (religious affiliation, spiritual beliefs, or values that
promote better access to health services), “education”
(assumes that high parental educational level, or health
literacy and numeracy, is an advantage), “socioeconomic
status” (access to resources and privilege with greater
household wealth, as an advantage), and “social capital”
(benefits obtained by individuals due to their social rela-
tionships, as an advantage).
For each factor of inequality, we hypothesized different
social gradients: (1) a positive gradient, when better gly-
cemic outcomes are found in more socially advantaged
groups; (2) a negative gradient, when better outcomes
are found in less advantaged groups; and (3) a neutral
gradient, when no significant differences exist between
groups. The results will be summarized with the aid of a
harvest plot, which is a graphical technique that helps to
illustrate a narrative synthesis [28].
Study selection and data extraction
Two reviewers will work independently to check eligibility
of studies (title and abstract and, if needed, full-text) and
extract the appropriate information in full-text articles.
Disagreements will be resolved by consensus. Assessment
of eligibility and its inclusion will be conducted according
to the indications of the PRISMA statement. Data to be
extracted from articles include the year of publication,
country, study design and period of data collection, base-
line characteristics of participants, interventions and com-
parators, factors of inequalities at baseline, and outcomes
(Tables 1 and 2).
The glycemic endpoints include (1) the mean value
of HbA1c (percentage), assessed preferably at the end
of the study, (2) the number of serious, severe and/or
nocturnal hypoglycemia episodes [≤ 3.0 mmol/L (54
mg/dL) or an event associated with severe cognitive
impairment (including coma and convulsions) requir-
ing assistance], (3) the number of patients with ≥ 1
DKA event, and (4) the percentage of time spent in
range [percentage of readings in the glycemic range
of 3.9–10.0 mmol/L (70–180 mg/dL) per unit of time]
or in hypo [< 3.9 mmol/L (< 70 mg/dL)] and hypergly-
cemia [> 10 mmol/L (> 180 mg/dL)] [23, 29–32]. PRO
will be captured with the HRQoL questionnaires.
When necessary, authors of eligible studies will be
contacted to provide additional information.
Assessment of risk of bias
Two reviewers will independently assess the risk of
bias of each study using two different tools: the
Cochrane Risk of Bias form RCT and the RTI Item
Bank for NRS [33, 34]. A review of only RCT may
provide insufficient information on vulnerable sub-
populations. Still, the inclusion of NRS may increase
the challenges in establishing causal inference because
they are at greater risk of bias than RCT, resulting
from confounding by indication and selection bias. In
contrast, threats to validity from performance and de-
tection bias, and to precision from the inadequate
sample size, should not differ markedly between RCT
and NRS (although some features such as blinding of
assessors that protect against detection bias are more
likely in experimental designs than in observational
studies). By including NRS (mainly registries), we may
capture valuable information on the intended popula-
tion for whom CSII is preferred, because registries
are larger, studied over a longer time, and may better
reflect all subgroups of patients and routine clinical
practice [3].
Statistical analysis
We will summarize the main characteristics of se-
lected studies, including the study’s objectives and
design, characteristics of study participants, interven-
tion and comparator, inclusion of PROGRESS cat-
egories, and outcomes (Tables 1 and 2). Effects
across the studies will be summarized with (1) the
pooled mean difference for HbA1c; (2) the pooled
rate ratio for hypoglycemia; (3) the pooled risk ratio
for DKA; (4) the mean difference in percentage of
time that blood glucose concentration remained in
target range, in hypo- or in hyperglycemia; and (5)
the pooled standardized mean difference (SMD) for
quality of life outcomes, with their 95% confidence
interval (CI), calculated with inverse variance ran-
dom effects models to incorporate the level of het-
erogeneity found across studies [25, 35]. The effect
size of the SMD will be classified as small (0.1–0.3),
medium (0.3–0.6) or large (≥ 0.6) [36]. Heterogeneity
among studies will be assessed with the I2 statistic,
whose values will be classified as follows: no relevant
heterogeneity (0–25%), moderate heterogeneity (25–
50%), and substantial heterogeneity (> 50%) [37].
Meta-analyses will be performed separately for RCTs
and NRS when data are available for at least two
studies with comparable results. For equity out-
comes, results will be summarized as a narrative syn-
thesis [28]. Publication bias will be evaluated
graphically using a funnel plot and also with the
method of Egger et al. [37]. The strength of the
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body of evidence will be assessed using the Grading
of Recommendations Assessment, Development and
Evaluation (GRADE) tool [38].
Subgroup analysis
Subgroup analyses will be performed based on age
group, length of follow-up, and the use of adjunctive
Table 2 PROGRESS framework to guide health equity data extraction on type 1 diabetes
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technological therapies that might directly improve gly-
cemic outcomes.
Sensitivity analysis
The analyses will be repeated after exclusion of studies
with a high risk of bias, and separately for RCT and
NRS.
Discussion
Given the increase of worldwide incidence of T1D, the
wider use of the CSII pump among some specific socio-
economic and demographic groups, and the lack of evi-
dence of its superiority when compared with the
conventional therapy using MDI, there is a need to crit-
ically assess the rise of inequalities in treatment selection
[39]. Furthermore, the inclusion of PRO captured by
health-related quality of life questionnaires will contrib-
ute to a complete diabetes measures portfolio [40].
Hence, the assessment of the effects of CSII versus MDI
on glycemic outcomes, across social factors defined by
PROGRESS, may contribute better to understand their
impact on health equity [12, 16, 41, 42].
A major issue will probably be the limited data re-
ported in the reviewed studies on the PROGRESS fac-
tors. For this reason, supplementary information will
also be gathered from authors of the included studies.
We are aware that the lack of important published infor-
mation on equity may be a limitation of our review.
The results of an equity-oriented SRMA may yield an
opportunity to discuss not only the effects of such inter-
ventions on glycemic endpoints, but also the existing
gap of information in the included studies regarding so-
cial inequities; it will pave the way to use those results to
orient clinical practice, equity-based research, and health
policy formulation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-019-1171-9.
Additional file 1. Search Strategies.
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